UBS analyst Eliana Merle upgrades CureVac (NASDAQ:CVAC) from Neutral to Buy and announces $18 price target.
Clearside Biomedical Presents Data at The Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting
Clearside Biomedical, Inc. (Nasdaq: CLSD) announced today that several key poster presentations were delivered on the Company's suprachoroidal injection delivery platform at The Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting.
